Report Detail

Other Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Status and Forecast 2019-2025

  • RnM2744029
  • |
  • 11 April, 2019
  • |
  • Global
  • |
  • 95 Pages
  • |
  • QYResearch
  • |
  • Other

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016.
The classification of Amyotrophic Lateral Sclerosis (ALS) Treatment includes Riluzole, Edaravone (Radicava) and Other and the proportion of Edaravone (Radicava) in 2017 is about 67.7%, Radicava is approved in Japan and Korea in 2015, and through the FDA in 2017.
In 2018, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was 240 million US$ and it is expected to reach 380 million US$ by the end of 2025, with a CAGR of 6.9% during 2019-2025.

This report focuses on the global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in United States, Europe and China.

The key players covered in this study
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma

Market segment by Type, the product can be split into
Riluzole
Edaravone (Radicava)
Other

Market segment by Application, split into
Hospital
Drugs Store
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Amyotrophic Lateral Sclerosis (ALS) Treatment status, future forecast, growth opportunity, key market and key players.
To present the Amyotrophic Lateral Sclerosis (ALS) Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Amyotrophic Lateral Sclerosis (ALS) Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Riluzole
      • 1.4.3 Edaravone (Radicava)
      • 1.4.4 Other
    • 1.5 Market by Application
      • 1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospital
      • 1.5.3 Drugs Store
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size
    • 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Regions
      • 2.2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Manufacturers
      • 3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Head office and Area Served
    • 3.3 Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Product/Solution/Service
    • 3.4 Date of Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2014-2019)
    • 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2014-2019)
    • 5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in United States
    • 5.3 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
    • 5.4 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2014-2019)
    • 6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Europe
    • 6.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
    • 6.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

    7 China

    • 7.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2014-2019)
    • 7.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in China
    • 7.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
    • 7.4 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2014-2019)
    • 8.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Japan
    • 8.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
    • 8.4 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2014-2019)
    • 9.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
    • 9.4 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

    10 India

    • 10.1 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2014-2019)
    • 10.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in India
    • 10.3 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
    • 10.4 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2014-2019)
    • 11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players in Central & South America
    • 11.3 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
    • 11.4 Central & South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Mitsubishi Tanabe Pharma
      • 12.1.1 Mitsubishi Tanabe Pharma Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.1.5 Mitsubishi Tanabe Pharma Recent Development
    • 12.2 Sanofi
      • 12.2.1 Sanofi Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.2.5 Sanofi Recent Development
    • 12.3 Mylan Pharma
      • 12.3.1 Mylan Pharma Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.3.5 Mylan Pharma Recent Development
    • 12.4 Apotex
      • 12.4.1 Apotex Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.4.5 Apotex Recent Development
    • 12.5 Glemark Generics
      • 12.5.1 Glemark Generics Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.5.5 Glemark Generics Recent Development
    • 12.6 Covis Pharma
      • 12.6.1 Covis Pharma Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.6.5 Covis Pharma Recent Development
    • 12.7 Sun Pharma
      • 12.7.1 Sun Pharma Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.7.5 Sun Pharma Recent Development
    • 12.8 Lunan Pharma
      • 12.8.1 Lunan Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
      • 12.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2014-2019)
      • 12.8.5 Lunan Pharma Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Summary:
      Get latest Market Research Reports on Amyotrophic Lateral Sclerosis (ALS) Treatment . Industry analysis & Market Report on Amyotrophic Lateral Sclerosis (ALS) Treatment is a syndicated market report, published as Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,131.70
      4,697.55
      6,263.40
      3,662.10
      5,493.15
      7,324.20
      602,706.00
      904,059.00
      1,205,412.00
      325,962.00
      488,943.00
      651,924.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report